CN112243375A - 选择性syk抑制剂的使用方法及药物组合物 - Google Patents

选择性syk抑制剂的使用方法及药物组合物 Download PDF

Info

Publication number
CN112243375A
CN112243375A CN201980017916.9A CN201980017916A CN112243375A CN 112243375 A CN112243375 A CN 112243375A CN 201980017916 A CN201980017916 A CN 201980017916A CN 112243375 A CN112243375 A CN 112243375A
Authority
CN
China
Prior art keywords
ophthalmic composition
compound
ocular
inflammation
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980017916.9A
Other languages
English (en)
Chinese (zh)
Inventor
安贾莉·潘迪
马修·查宾
哈罗德·帕特森
徐勇岳
马克·阿贝尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aura Co Ltd
Portola Pharmaceuticals LLC
Original Assignee
Aura Co Ltd
Portola Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aura Co Ltd, Portola Pharmaceuticals LLC filed Critical Aura Co Ltd
Priority to CN202411182880.9A priority Critical patent/CN119235862A/zh
Publication of CN112243375A publication Critical patent/CN112243375A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980017916.9A 2018-03-09 2019-03-08 选择性syk抑制剂的使用方法及药物组合物 Pending CN112243375A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411182880.9A CN119235862A (zh) 2018-03-09 2019-03-08 选择性syk抑制剂的使用方法及药物组合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862641094P 2018-03-09 2018-03-09
US62/641,094 2018-03-09
US201862663999P 2018-04-27 2018-04-27
US62/663,999 2018-04-27
PCT/US2019/021402 WO2019173744A1 (en) 2018-03-09 2019-03-08 Methods of use and pharmaceutical compositions of a selective syk inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411182880.9A Division CN119235862A (zh) 2018-03-09 2019-03-08 选择性syk抑制剂的使用方法及药物组合物

Publications (1)

Publication Number Publication Date
CN112243375A true CN112243375A (zh) 2021-01-19

Family

ID=65818744

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980017916.9A Pending CN112243375A (zh) 2018-03-09 2019-03-08 选择性syk抑制剂的使用方法及药物组合物
CN202411182880.9A Pending CN119235862A (zh) 2018-03-09 2019-03-08 选择性syk抑制剂的使用方法及药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411182880.9A Pending CN119235862A (zh) 2018-03-09 2019-03-08 选择性syk抑制剂的使用方法及药物组合物

Country Status (15)

Country Link
US (1) US20210052582A1 (https=)
EP (1) EP3761986A1 (https=)
JP (1) JP7417531B2 (https=)
KR (1) KR20210018193A (https=)
CN (2) CN112243375A (https=)
AU (1) AU2019230220B2 (https=)
BR (1) BR112020018377A2 (https=)
CA (1) CA3093371A1 (https=)
IL (1) IL277093A (https=)
MX (1) MX2020009396A (https=)
PH (1) PH12020551418A1 (https=)
SG (1) SG11202008765UA (https=)
TW (1) TWI805705B (https=)
WO (1) WO2019173744A1 (https=)
ZA (1) ZA202005459B (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
US8318755B2 (en) * 2008-04-16 2012-11-27 Portola Pharmaceuticals, Inc. Inhibitors of SYK and JAK protein kinases
US20130274216A1 (en) * 2012-04-12 2013-10-17 Alcon Research, Ltd. Treatment for microbe-induced inflammatory responses in the eye

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007056457A2 (en) * 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
KR101454674B1 (ko) 2006-03-17 2014-10-27 존슨 앤드 존슨 비젼 케어, 인코포레이티드 산화에 불안정한 성분을 포함하는 안정화된 안과용 조성물
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
EP2897950A1 (en) * 2012-09-18 2015-07-29 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009136995A2 (en) * 2008-04-16 2009-11-12 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
US8318755B2 (en) * 2008-04-16 2012-11-27 Portola Pharmaceuticals, Inc. Inhibitors of SYK and JAK protein kinases
US20130274216A1 (en) * 2012-04-12 2013-10-17 Alcon Research, Ltd. Treatment for microbe-induced inflammatory responses in the eye

Also Published As

Publication number Publication date
SG11202008765UA (en) 2020-10-29
US20210052582A1 (en) 2021-02-25
TWI805705B (zh) 2023-06-21
AU2019230220A1 (en) 2020-10-08
KR20210018193A (ko) 2021-02-17
PH12020551418A1 (en) 2021-09-01
MX2020009396A (es) 2021-01-15
IL277093A (en) 2020-10-29
BR112020018377A2 (pt) 2021-03-09
AU2019230220B2 (en) 2025-01-30
CN119235862A (zh) 2025-01-03
JP2021517139A (ja) 2021-07-15
CA3093371A1 (en) 2019-09-12
EP3761986A1 (en) 2021-01-13
JP7417531B2 (ja) 2024-01-18
WO2019173744A1 (en) 2019-09-12
ZA202005459B (en) 2023-02-22
TW202002980A (zh) 2020-01-16

Similar Documents

Publication Publication Date Title
CN1753683B (zh) 预防和治疗不良眼部病症的眼用制剂
KR100889170B1 (ko) 안구 건조의 치료에 있어서 리멕솔론의 용도
EP4272743A2 (en) Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
CN105792815A (zh) 用于治疗远视眼的组合物和方法
US20210177807A1 (en) Compositions for the treatment and prevention of eyelid swelling
AU2011274245B2 (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
WO2009061431A2 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
JP2013522312A (ja) セチリジンの眼用製剤、および使用方法
WO2017066052A1 (en) Formulations and methods for treating high intraocular pressure
CN118922190A (zh) 用于治疗眼病的组合物及方法
US20050239745A1 (en) Novel topical ophthalmic formulations
TW202245810A (zh) 散光之治療
WO2023024126A1 (zh) 一种含伏立康唑的眼用凝胶剂及其制备方法与应用
JP7417531B2 (ja) 選択的ｓｙｋ阻害剤の使用方法および医薬組成物
KR20240050324A (ko) 빈포세틴을 사용한 근시치료방법
JP2024515714A (ja) 散瞳、緑内障、及び他の眼の病態を治療するための方法及び組成物
Smith et al. Tolerability, pharmacokinetics, and pharmacodynamics of a brinzolamide episcleral sustained release implant in normotensive New Zealand white rabbits
Gibson 12 Ophthalmic dosage forms
MX2011005586A (es) Composiciones de soluciones oculares topicas para suministrar concentraciones efectivas de agente activo al segmento posterior del ojo.
WO2025049378A1 (en) Netarsudil ophthalmological formulations with less toxicity
HK40128453A (zh) 用於治疗老花眼的组合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20210119

RJ01 Rejection of invention patent application after publication